AmacaThera Analysis: $15M Raised
What is AmacaThera?
AmacaThera is a clinical-stage biotechnology company developing an injectable hydrogel platform for localized, sustained drug delivery. Their technology aims to improve patient outcomes across various therapeutic areas, including post-surgical pain management and cancer treatment. The company is grounded in the research of Dr. Molly Shoichet, a prominent biomaterials scientist.
Location
160 College Street, Toronto, Ontario M5S 3E1, Canada
Employees
1-10
Founded
2016
Funding Status
Series A
Product Features & Capabilities
- Injectable hydrogel platform
- AMT-143 for non-opioid pain management
- Advanced sustained release formulations
Use Cases
Administer localized drug delivery for post-surgical pain; Evaluate AMT-143 in human studies; Develop formulations for cancer treatment; Provide sustained release of therapeutics; Collaborate with partners for drug development
Other Considerations
Closed CAD$4.0 million Series A extension; Exclusive global licensing agreement with Pacira BioSciences; Dosed first human subject with AMT-143; Featured in RBCx media coverage
See something that needs updating? Suggest edits to this profile.